Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Delivery of CD109-based peptides to antagonize TGF-beta in a murine model of wound healing

FY 2014-15

Summary
"Hypertrophic scarring is a fibrotic skin disorder characterized by excessive deposition of extracellular matrix components occurring after trauma to the dermis. To date, treatment options remain limited. Our group has discovered that CD109, a TGF-β co-receptor, antagonizes TGF-β signaling and inhibits extracellular matrix production. Our laboratory has engineered CD109-based peptides that correspond to the TGF-β binding region, with preliminary in vitro data indicating anti-fibrotic properties. The proposed project aims to test the anti-fibrotic effects of CD109-based peptides delivered to a mouse model of hypertrophic scarring via a subcutaneous osmotic pump. Skin samples will be examined histologically, and markers of fibrosis and inflammation will be measured by real-time polymerase chain reaction for gene expression, immunofluorescence, and Western blot analysis for protein expression. The proposed research is highly feasible as it uses an existing animal model and well established tissue processing and analysis methods. It will provide the basis for a unique therapeutic approach for patients suffering from debilitating scars. Factors that delay, halt or reverse progression of hypertrophic scarring will reduce health care costs significantly. The delivery of these peptides in vivo models of hypertrophic scars represents a critical step in the pre-clinical development of our solution to address this major challenge in wound healing."
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
332606
Name
XU Liqin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Delivery of CD109-based peptides to antagonize TGF-beta in a murine model of wound healing
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cd109; Hypertrophic Scar; Tgf-Beta; Wound Healing
Abstract
"Hypertrophic scarring is a fibrotic skin disorder characterized by excessive deposition of extracellular matrix components occurring after trauma to the dermis. To date, treatment options remain limited. Our group has discovered that CD109, a TGF-β co-receptor, antagonizes TGF-β signaling and inhibits extracellular matrix production. Our laboratory has engineered CD109-based peptides that correspond to the TGF-β binding region, with preliminary in vitro data indicating anti-fibrotic properties. The proposed project aims to test the anti-fibrotic effects of CD109-based peptides delivered to a mouse model of hypertrophic scarring via a subcutaneous osmotic pump. Skin samples will be examined histologically, and markers of fibrosis and inflammation will be measured by real-time polymerase chain reaction for gene expression, immunofluorescence, and Western blot analysis for protein expression. The proposed research is highly feasible as it uses an existing animal model and well established tissue processing and analysis methods. It will provide the basis for a unique therapeutic approach for patients suffering from debilitating scars. Factors that delay, halt or reverse progression of hypertrophic scarring will reduce health care costs significantly. The delivery of these peptides in vivo models of hypertrophic scars represents a critical step in the pre-clinical development of our solution to address this major challenge in wound healing."
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
XU, Liqin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~